European doctors challenge FDA's blanket ban on probiotics for premature infants
Leading European pediatric organizations are pushing back against the U.S. FDA's caution on probiotic use in preterm babies, arguing the agency's advisory is too strict. The dispute matters to hospitals, drugmakers, and regulators worldwide as it could reshape clinical practice and reshape the $50 billion global probiotics market.
Originaltitel: Reevaluating the FDA's warning against the use of probiotics in preterm neonates: a societal statement by ESPGHAN and EFCNI
<p>The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.</p>